Company News

Term: Company News

  • September 14, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul A. Friedman, M.D. has been appointed to serve on the Company’s Board of Directors, succeeding R. Douglas Norby, who has retired as a Director following 18 years of service to the Company. Alexion also announced that Director Alvin S. Parven advised the Board that he does not plan to stand for re-election at the Company’s next annual meeting of shareholders following 18 yearsmore...
  • September 13, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris® (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The new results show sustained treatment benefits across a range of MG-specific assessment scalesmore...
  • September 12, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019. The restructuring will reduce the Company’s global workforce by approximately 20%. The resulting savings will allow Alexion to prioritize investments tomore...
  • September 11, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.m. ET. Following the release, Alexion management will conduct a conference call and audio webcast on Tuesday, September 12, 2017 at 8:30 a.m. ET. To participate in this conference call, dial 800-406-5345 (USA) or 719-325-4744 (International),more...
  • September 5, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Morgan Stanley 15th Annual Global Healthcare Conference in New York on Tuesday, September 12, 2017 at 2:55 p.m., Eastern Time. LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York on Wednesday, September 27, 2017 at 9:00 a.m., Eastern Time. An audio webcast ofmore...
  • August 21, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients withmore...
  • August 15, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patents No. 9,732,149; 9,718,880; and 9,725,504, which are directed to the composition of matter of eculizumab (Soliris®), pharmaceutical formulations of eculizumab, and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab, respectively, and which will expire in 2027. “Alexion ismore...
  • August 10, 2017
    NEW HAVEN, Conn. & STAMFORD, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Sema4 today announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases.“The world-classmore...
  • July 27, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2017. Total revenues in the quarter were $912 million, a 21 percent increase compared to the same period in 2016. Second quarter revenue reflected a benefit of approximately $35 million due to favorable timing of orders compared to our prior forecast. The negative impact of foreign currency on total revenue year-over-year was 2 percent or $12more...
  • July 11, 2017
    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter 2017 on Thursday, July 27, 2017 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast to discuss the second quarter 2017 financial results and strategic update on Thursday, July 27, 2017, at 10:00 a.m. Eastern Timemore...